Lactobacillus reuteri UALre-16 and Reduced Hospitalization Duration

• Systematic Review with Meta-Analysis: Lactobacillus reuteri DSM 17938 for Treating Acute Gastroenteritis in Children. An Update

  • 2019-11-14
  • Meta-Analysis
  • Nutrients 11(11)
  • • B. Patro-Gołąb
    • H. Szajewska

  • PubMed: 31739457
  • DOI: 10.3390/nu11112762

  2 Insights on

  • Reduced Hospitalization Duration

  • High evidence

  L. reuteri use was also associated with a reduced duration of hospitalization (three RCTs, n = 284, MD -0.54 days, 95% CI [-1.09, 0.0]).

  Effect

  Beneficial

  Effect size

  Small

  Significant

  No

• Lack of Efficacy of Lactobacillus reuteri DSM 17938 for the Treatment of Acute Gastroenteritis: A Randomized Controlled Trial.

  • 2019-10
  • RCT · n = 100
  • Pediatric Infectious Disease Journal 38(10)
  • • H. Szymański
    • H. Szajewska

  • PubMed: 31033909
  • DOI: 10.1097/INF.0000000000002355

  2 Insights on

  • Reduced Hospitalization Duration

  • High evidence

  Compared with the placebo group, patients in the L. reuteri group had a shorter duration of hospitalization (P = 0.048).

  Effect

  Beneficial

  Effect size

  Small

  Significant

  Yes

• Lactobacillus reuteri DSM 17938 as a Probiotic for Preterm Neonates: A Strain-Specific Systematic Review.

  • 2015-06-09
  • Systematic Review
  • Journal of Parenteral and Enteral Nutrition 40(6)
  • • G. Athalye-Jape
    • Shripada C Rao
    • S. Patole

  • PubMed: 26059900
  • DOI: 10.1177/0148607115588113

  17 Insights on

  • Reduced Hospitalization Duration

  • High evidence

  Meta-analysis of RCTs estimated that the duration of hospitalization (-10.77 days; 95% CI, -13.67 to -7.86; 3 RCTs) was reduced in the L reuteri group.

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes